These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21523723)

  • 1. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
    Brooks HD; Glisson BS; Bekele BN; Johnson FM; Ginsberg LE; El-Naggar A; Culotta KS; Takebe N; Wright J; Tran HT; Papadimitrakopoulou VA
    Cancer; 2011 May; 117(10):2112-9. PubMed ID: 21523723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
    Miller AA; Pang H; Hodgson L; Ramnath N; Otterson GA; Kelley MJ; Kratzke RA; Vokes EE;
    J Thorac Oncol; 2010 Mar; 5(3):380-4. PubMed ID: 20087228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 trial of dasatinib in advanced melanoma.
    Kluger HM; Dudek AZ; McCann C; Ritacco J; Southard N; Jilaveanu LB; Molinaro A; Sznol M
    Cancer; 2011 May; 117(10):2202-8. PubMed ID: 21523734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
    Herold CI; Chadaram V; Peterson BL; Marcom PK; Hopkins J; Kimmick GG; Favaro J; Hamilton E; Welch RA; Bacus S; Blackwell KL
    Clin Cancer Res; 2011 Sep; 17(18):6061-70. PubMed ID: 21810917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
    Johnson FM; Bekele BN; Feng L; Wistuba I; Tang XM; Tran HT; Erasmus JJ; Hwang LL; Takebe N; Blumenschein GR; Lippman SM; Stewart DJ
    J Clin Oncol; 2010 Oct; 28(30):4609-15. PubMed ID: 20855820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Schilder RJ; Brady WE; Lankes HA; Fiorica JV; Shahin MS; Zhou XC; Mannel RS; Pathak HB; Hu W; Alpaugh RK; Sood AK; Godwin AK
    Gynecol Oncol; 2012 Oct; 127(1):70-4. PubMed ID: 22710075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
    Finn RS; Bengala C; Ibrahim N; Roché H; Sparano J; Strauss LC; Fairchild J; Sy O; Goldstein LJ
    Clin Cancer Res; 2011 Nov; 17(21):6905-13. PubMed ID: 22028489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
    Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
    Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
    Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
    Argiris A; Feinstein TM; Wang L; Yang T; Agrawal S; Appleman LJ; Stoller RG; Grandis JR; Egloff AM
    Invest New Drugs; 2012 Aug; 30(4):1575-84. PubMed ID: 21881918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.
    Tsao A; Hui EP; Juergens R; Marur S; Huat TE; Cher GB; Hong RL; Hong WK; Chan AT
    Cancer Med; 2013 Jun; 2(3):351-9. PubMed ID: 23930212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
    Geiger JL; Bauman JE; Gibson MK; Gooding WE; Varadarajan P; Kotsakis A; Martin D; Gutkind JS; Hedberg ML; Grandis JR; Argiris A
    Head Neck; 2016 Dec; 38(12):1759-1764. PubMed ID: 27232378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
    Stabile LP; Egloff AM; Gibson MK; Gooding WE; Ohr J; Zhou P; Rothenberger NJ; Wang L; Geiger JL; Flaherty JT; Grandis JR; Bauman JE
    Oral Oncol; 2017 Jun; 69():38-45. PubMed ID: 28559019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
    Mayer EL; Baurain JF; Sparano J; Strauss L; Campone M; Fumoleau P; Rugo H; Awada A; Sy O; Llombart-Cussac A
    Clin Cancer Res; 2011 Nov; 17(21):6897-904. PubMed ID: 21903773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
    Johnson FM; Agrawal S; Burris H; Rosen L; Dhillon N; Hong D; Blackwood-Chirchir A; Luo FR; Sy O; Kaul S; Chiappori AA
    Cancer; 2010 Mar; 116(6):1582-91. PubMed ID: 20108303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
    Machiels JP; Licitra LF; Haddad RI; Tahara M; Cohen EE
    BMC Cancer; 2014 Jun; 14():473. PubMed ID: 24973959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
    Takahashi S; Miyazaki M; Okamoto I; Ito Y; Ueda K; Seriu T; Nakagawa K; Hatake K
    Cancer Sci; 2011 Nov; 102(11):2058-64. PubMed ID: 21781226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.